Skip to content

Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970
515.02 -5.64 -1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 529.99 +1.79%
After-hours 515.02 0.00%
Overnight 523.41 +0.53%
558.88425.09515.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VRTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +8.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 33.1x Better than 19%
Forward P/E 34.1x Better than 14%
Price / Sales 10.5x Better than 10%
P/E vs own 5-yr range 99th pctl Better than 3%
Growth B-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 10.4% Better than 65%
Net income CAGR (3Y) 6.0% Better than 52%
Free cash flow CAGR (3Y) -6.6% Better than 31%
Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 86.2% Better than 94%
Operating margin 37.9% Better than 94%
Net margin 32.9% Better than 92%
Return on equity 22.5% Better than 81%
Return on invested capital 18.3% Better than 87%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -6.0% Better than 60%
6-month return 18.5% Better than 81%
12-month return (ex latest month) 22.8% Better than 62%
Distance below 52-week high 9.4% Better than 85%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.9x Better than 72%
Debt to assets 7.9% Better than 73%
Interest coverage 350.1x Better than 97%
Free cash flow / net income 80.8% Better than 26%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 95.2% Better than 77%
Upside to average target 21.1% Better than 35%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.38%
1M +0.07%
3M -4.67%
6M +19.65%
YTD +13.60%
1Y +21.95%
3Y +44.33%
5Y +181.62%

Key statistics

Price & volume

Prev close
520.66
Open
529.94
Day range
513.80 - 531.37
Avg price
519.15
Volume
1.77M
Turnover
917.82M
Amplitude
3.38%
52-week range
412.27 - 568.67

Valuation

P/E
33.62
P/E (TTM)
33.14
P/B
6.25
EPS
15.32
Net profit
3.88B
Net assets
20.91B

Share structure

Market cap
130.58B
Float cap
130.19B
Shares out
253.54M
Float shares
252.79M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 66% of range
412.27 568.67

9.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+5.74M net over the window

Short interest

Shares short
4.81M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals last traded at 515.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Vertex Pharmaceuticals's market cap?

About 130.58B.

What is the P/E ratio of Vertex Pharmaceuticals?

The trailing twelve-month P/E is 33.14. The Valuation tab shows it against the stock's own five-year range.

Does Vertex Pharmaceuticals pay a dividend?

Vertex Pharmaceuticals does not currently pay a regular dividend.

Is Vertex Pharmaceuticals a buy according to analysts?

The consensus of 21 analysts is a Buy rating, with an average 12-month price target of 623.65, which implies 21.1% upside from the current price. This is not investment advice.

What is Vertex Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Vertex Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.

Vertex Pharmaceuticals discussion 0 comments

Add a comment